Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab + cobimetinib + palbociclib for advanced or metastatic colorectal cancer with BRAF or KRAS mutations
ACTRN12621001436864Phase 2Terminated
- Sponsor
- Cothera Bioscience
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cetuximab, cobimetinib and palbociclib in colorectal cancer (CRC) (7 arms), sponsored by Cothera Bioscience. Primary endpoints: Dose-limiting toxicity and Objective response rate. Started Dec 2021; status: terminated.
02
Drugs
cetuximabcobimetinibpalbociclib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ACTRN12621001436864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001436864.